Zhang F F, Arber D A, Wilson T G, Kawachi M H, Slovak M L
Departments of Cytogenetics, City of Hope National Medical Center, Duarte, California 91010, USA.
Clin Cancer Res. 1997 Dec;3(12 Pt 1):2317-28.
Fluorescence in situ hybridization (FISH) is regarded as a potential new tool for the clinical management of bladder cancer that works by detecting cytogenetic aberrations in noncycling, exfoliated cells from bladder irrigations. However, clinical validation steps must be addressed to define the true predictive potential in a clinical setting. Toward the validation of FISH with the use of bladder washings and prior to incorporation into a large, prospective clinical trial, a pilot study was designed to determine its clinical potential, define testing limitations, optimize a panel of probes specific for bladder cancer detection, and outline protocol/data collection parameters. Correlations with standard cytogenetics and clinicopathological features of bladder cancer were investigated. Exfoliated cells obtained from benign bladder washings served as normal controls. The results of this pilot study suggest the following: (a) FISH and cytology are complementary testing procedures; however, the FISH data provided valuable ploidy and specific genotypic information for recurrent tumors in "suspicious" cases; (b) chromosomal aberrations defined by FISH are associated with tumor grade and stage (i.e., simple numerical aberrations were associated with low-grade tumors, and high-grade and invasive tumors exhibited multiple, nonrandom chromosomal aberrations and vast intratumor heterogeneity); (c) somatic pairing or homologous centromeric association can give a false-positive result and appears to be linked to prior therapy; (d) dual hybridization with reference gene-specific probes must be used to control for somatic pairing; and (e) focal, deep muscle invasive lesions, with no surface exposure, may yield false-negative results. The data suggest that FISH analysis, with the use of cells isolated from bladder washings, is a powerful technique holding promise for early cancer detection, monitoring treatment outcome, and predicting recurrence of disease.
荧光原位杂交(FISH)被视为膀胱癌临床管理的一种潜在新工具,其工作原理是检测膀胱冲洗液中处于非循环状态的脱落细胞的细胞遗传学畸变。然而,必须进行临床验证步骤,以确定其在临床环境中的真正预测潜力。为了在使用膀胱冲洗液的情况下验证FISH,并将其纳入大型前瞻性临床试验之前,设计了一项试点研究,以确定其临床潜力、定义检测局限性、优化一组用于检测膀胱癌的特异性探针,并概述方案/数据收集参数。研究了与膀胱癌标准细胞遗传学和临床病理特征的相关性。从良性膀胱冲洗液中获得的脱落细胞用作正常对照。这项试点研究的结果表明:(a)FISH和细胞学是互补的检测程序;然而,FISH数据为“可疑”病例中的复发性肿瘤提供了有价值的倍性和特定基因型信息;(b)FISH定义的染色体畸变与肿瘤分级和分期相关(即简单的数值畸变与低级别肿瘤相关,高级别和浸润性肿瘤表现出多个非随机染色体畸变和广泛的肿瘤内异质性);(c)体细胞配对或同源着丝粒关联可产生假阳性结果,且似乎与先前的治疗有关;(d)必须使用与参考基因特异性探针的双重杂交来控制体细胞配对;(e)没有表面暴露的局灶性、深部肌肉浸润性病变可能产生假阴性结果。数据表明,使用从膀胱冲洗液中分离的细胞进行FISH分析是一种强大的技术,有望用于早期癌症检测、监测治疗结果和预测疾病复发。